S-1: Carmell Corp Files for Resale of 1.33 Million Shares After Private Placement

Carmell Corporation files an S-1 registration statement for the resale of 1,331,452 shares of common stock by selling stockholders following a recent private placement.

Summary

• Carmell Corporation has filed an S-1 registration statement for the resale of up to 1,331,452 shares of its common stock by selling stockholders.
• The shares were issued to the selling stockholders pursuant to a Securities Purchase Agreement dated April 4, 2024, in a private placement that closed on April 11, 2024.
• The company will not receive any proceeds from the sale of these shares.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol CTCX.
• On May 9, 2024, the last reported sale price of the common stock was $2.18 per share.
• Carmell is a bio-aesthetics company focused on skin and hair health, utilizing the Carmell Secretome.
• The company is also developing regenerative bone and tissue healing products.
• On March 26, 2024, the company completed the sale of its subsidiary Axolotl Biologix, LLC (AxoBio) to its former stockholders.
• The consideration for the AxoBio sale included the return of 3,845,337 shares of the company's common stock and 4,243 shares of Series A Convertible Voting Preferred Stock, as well as the cancellation of $8 million in notes payable.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of certain reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily providing factual information about the resale of shares and the company's business activities. The inclusion of risk factors tempers any positive sentiment.

Positives

• The company completed the sale of its subsidiary Axolotl Biologix, LLC (AxoBio) to its former stockholders, which will reduce operating expenses.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of certain reduced public company reporting requirements.

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.
• The company has limited experience as a commercial company and may not be successful in commercializing its products.
• The company faces substantial competition in the cosmetics industry.
• The company may require additional capital to support its growth plans, and such capital may not be available on terms acceptable to it, if at all.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company may become involved in litigation that may materially adversely affect it.
• The current economic downturn may harm the company's business and results of operations.
• The company will need to grow the size of its organization in the future, and it may experience difficulties in managing this growth.
• The price of the company's common stock may be volatile and may fluctuate substantially.

Future Outlook

The company plans to launch a line of cosmetic skincare products in the first half of 2024 and expects revenue from these products and cost savings from restructuring to extend its cash runway.

Industry Context

The document relates to a company operating in the bio-aesthetics and regenerative medicine industries, which are experiencing growth and innovation.

Stakeholder Impact

• The resale of shares may impact the share price and trading volume of the company's stock.
• The company's future performance will depend on its ability to manage growth, commercialize products, and compete effectively.

Next Steps

• The selling stockholders may offer and sell the shares of common stock from time to time.
• The company will work to maintain the effectiveness of the registration statement.

Key Dates

Keywords

common stock, resale, private placement, AxoBio, Carmell Corporation, registration statement, securities